Nasdaq Grants VYNE Therapeutics Extension to Regain Minimum Bid Price Compliance

summarizeSummary

VYNE Therapeutics Inc. received a 180-day extension from Nasdaq to regain compliance with the minimum $1.00 bid price requirement, pushing the deadline to September 7, 2026.

check_boxKey Events

• Delisting Deadline Missed

  VYNE Therapeutics failed to regain compliance with Nasdaq's minimum $1.00 bid price requirement by the initial March 10, 2026 deadline.

• Nasdaq Grants Extension

  The company received an additional 180 calendar days, until September 7, 2026, to meet the minimum bid price rule.

• Potential Reverse Stock Split

  VYNE Therapeutics indicated it may consider a reverse stock split to cure the bid price deficiency during the extended compliance period.

• Continued Listing Uncertainty

  The stock will continue to trade on Nasdaq for now, but faces potential delisting if compliance is not achieved by the new deadline.

auto_awesomeAnalysis

This 8-K confirms VYNE Therapeutics failed to meet Nasdaq's minimum bid price requirement by the initial March 10, 2026 deadline. While the granted extension provides a temporary reprieve, it underscores the company's ongoing struggle with its stock price, especially following the highly dilutive reverse merger announced in late February. The company's intention to consider a reverse stock split to cure the deficiency often signals further challenges for existing shareholders. Investors should monitor the stock's performance and any further announcements regarding a reverse split or delisting.